Mineralys Therapeutics (NASDAQ:MLYS) Receives Outperform Rating from Lifesci Capital

Lifesci Capital restated their outperform rating on shares of Mineralys Therapeutics (NASDAQ:MLYS) in a report released on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS.

Mineralys Therapeutics Trading Down 0.5 %

Shares of MLYS opened at $12.78 on Tuesday. The firm has a 50-day moving average price of $13.17 and a 200 day moving average price of $10.10. The firm has a market capitalization of $634.27 million and a P/E ratio of -6.39. Mineralys Therapeutics has a 12-month low of $5.85 and a 12-month high of $17.70.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.24. Equities research analysts predict that Mineralys Therapeutics will post -2.64 earnings per share for the current fiscal year.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average cost of $13.50 per share, with a total value of $7,499,992.50. Following the completion of the acquisition, the insider now directly owns 5,074,916 shares of the company’s stock, valued at approximately $68,511,366. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Mineralys Therapeutics

Several large investors have recently modified their holdings of MLYS. Barclays PLC acquired a new stake in shares of Mineralys Therapeutics during the first quarter worth $196,000. California State Teachers Retirement System acquired a new stake in Mineralys Therapeutics during the first quarter worth approximately $70,000. Bank of New York Mellon Corp acquired a new position in shares of Mineralys Therapeutics in the 1st quarter valued at $521,000. Rhumbline Advisers acquired a new stake in shares of Mineralys Therapeutics in the first quarter worth $172,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Mineralys Therapeutics in the first quarter valued at $1,393,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.